Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight

Indian Journal of Endocrinology and Metabolism

Volumn 19, Issue 6, 2015, Pages 722-730

  Singh, Awadhesh Kumar ^a,b  

^a GD Hospital and Diabetes Institute   (India)

^b Sun Valley Diabetes Hospital   (India)

Author keywords

Ketoacidosis; ketonemia; ketonuria; ketosis; sodium glucose co transporter 2 inhibitors

Indexed keywords

EID: 84981335309     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.167554     Document Type: Review

References (42)

1. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502.
2. Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2013;22:463-86.
3. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2013;159:262-74.
4. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, et al. Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2014;16:984-93.
5. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2:pii: e001007.
6. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:457-66.
7. Singh AK. Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Indian J Endocrinol Metab 2014;18:617-23.
8. FDA Drug Safety Communication: FDA Warns that SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. [Last accessed on 2015 Jul 03].
9. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2-inhibitors/human-referral-prac-000052.jsp&mid=WC0b01ac05805c516f. [Last accessed on 2015 Jul 03].
10. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52.
11. Kalra S, Sahay R, Gupta Y. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab 2015;19:524-8.
12. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-9.
13. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-3.
14. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015;38(7):1181-8.
15. St Hilaire R, Costello H. Prescriber beware: Report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication. Am J Emerg Med 2014. pii: S0735-675700694-9.
16. Available from: http://www.typeonenation.org/groups/adults/forum/topic/invokana-fort1d/. [Last downloaded on 2015 Jul 03].
17. Kuhadiya N, Mehta A, Ghanim H, Hejna J, Makdissi A, Chaudhuri A, et al. American Association of Clinical Endocrinolgy Meeting 2015, Nashville, TN: Late-Breaking Abstract 1213. Available from: http://www.am2015.aace.com/sites/all/files/Late-Breaking.pdf. [Last accessed on 2015 Jul 03].
18. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015. pii: Dc150843. [Epub ahead of print]
19. Burr K, Nguyen AT, Rasouli N. Endocrine Society Meeting, San Diaego, California. SAT 586-604-Diabetes Case Reports II Clinical. 2015. Available from: https://www.endo.confex.com/endo/2015endo/webprogram/Paper21461.html. [Last accessed on 2015 Jul 03].
20. Chaudhury F. Diabetic ketoacidosis following SGLT2 inhibitor therapy in T2DM. American Association of Clinical Endocrinology Meeting 2015, Nashville, TN: Abstract 203. Available from: http://www.am2015.aace.com/sites/all/files/2015-Final-Abstract.pdf. [Last accessed on 2015 Jul 03].
21. Kelwade J, Sethi BK, Nagesh SV, Vaseem A. A case of 'pseudo-ketoacidosis'. Indian J Endocrinol Metab 2014;18:743.
22. Kohler S, Salsali A, Hantel S, Kim G, Woerle HJ, Broedl UC. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Poster Presentation. American Diabetic Association, Boston; 2014. p. 1173.
23. Erondu N, Desai M, Ways K, Meininger G. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015; Jul 22. pii: dc151251. [Epub ahead of print]
24. Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 2015;3:503-4.
25. Hayami T, Kato Y, Kamiya H, Kondo M, Naito E, Sugiura Y, et al. A case of ketoacidosis by a SGLT2 inhibitor in a diabetic patient with low carbohydrate diet. J Diabetes Investig 2015; DOI: 10.1111/jdi.12330. [Epub ahead of print]
26. Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: Results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411-9.
27. Dabelea D, Rewers A, Stafford JM, Standiford DA, Lawrence JM, Saydah S, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: The SEARCH for diabetes in youth study. Pediatrics 2014;133:e938-45.
28. Cohen JJ, Berglund F, Lotspeich WD. Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am J Physiol 1956;184:91-6.
29. Ruderman NB, Ross PS, Berger M, Goodman MN. Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J 1974;138:1-10.
30. Martin PM, Gopal E, Ananth S, Zhuang L, Itagaki S, Prasad BM, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem 2006;98:279-88.
31. Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74.
32. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65.
33. Nishimura R, Osonoi T, Jinnouchi H, Kanada S, Omiya H, Sakal S, et al. Low carbohydrate did not affect the behaviour of luseogliflozin, a selective SGLT2 inhibitor on glycemic control over 24 hours measured by continuous glucose monitoring in Japanese patients with type 2 diabetes. Poster Presentation. American Diabetes Association Meeting, Boston; 2015. p. 948.
34. Nakayama H, Yoshinobu S, Kawano S, Tsuruta M, Nohara M, Soga R, et al. Factors associated with the effect of ipragliflozin on the diurnal profiles of plasma glucose and 3-hydroxybutyrate in patient with type 2 diabetes. Poster Presentation. American Diabetes Association Meeting, Boston; 2015. p. 1236.
35. Song WJ, Mondal P, Wolfe A, Alonso LC, Stamateris R, Ong BW, et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab 2014;19:667-81.
36. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-14.
37. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
38. Smulders RA, Leeflang S, Schliess F. The effect of ipragliflozin on the total glucose turnover after OGTT in healthy subjects and patients with type 2 diabetes mellitus. Diabetologia 2013;56:S399-400.
39. Paquot N, Schneiter P, Jéquier E, Gaillard R, Lefèbvre PJ, Scheen A, et al. Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. Diabetologia 1996;39:580-6.
40. Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014;16:137-44.
41. Kalra S, Gupta Y, Patil S. Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions. Indian J Endocrinol Metab 2015;19:426-9.
42. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-7.